Who
Seth Loring Harrison
Director
Company insider
Files Form 4 as: Director and 10% owner, Stoke Therapeutics; Director and 10% owner, Akero Therapeutics; Director and 10% owner, HeartWare International; Director and 10% owner, Eledon Pharmaceuticals.
In numbers
- Trades disclosed
- 228
- Buys
- 19
- Sells
- 20
- Bought
- $75.5M
- Sold
- $126.4M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 13 Aug 2008
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,555 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —19,441 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —7,639 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —7,639 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,747 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,747 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —17,786 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —17,786 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,555 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,777 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,555 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —29,555 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,777 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,777 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —11,650 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —11,650 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —21,000 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —21,000 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —19,441 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code G | —19,441 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.